Eric W. P. Damen

450 total citations
13 papers, 368 citations indexed

About

Eric W. P. Damen is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Eric W. P. Damen has authored 13 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 4 papers in Organic Chemistry and 4 papers in Oncology. Recurrent topics in Eric W. P. Damen's work include Cancer Treatment and Pharmacology (4 papers), Carbohydrate Chemistry and Synthesis (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Eric W. P. Damen is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Carbohydrate Chemistry and Synthesis (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Eric W. P. Damen collaborates with scholars based in Netherlands, Finland and Germany. Eric W. P. Damen's co-authors include Hans W. Scheeren, Franciscus M. H. de Groot, Hans W. Scheeren, Ruben G.G. Leenders, Tapio Nevalainen, Ben McKay, Hidde J. Haisma, Dick de Vos, Marcel Hoogenraad and Pieter H.J. Houba and has published in prestigious journals such as Tetrahedron Letters, Current Medicinal Chemistry and Bioorganic & Medicinal Chemistry.

In The Last Decade

Eric W. P. Damen

12 papers receiving 349 citations

Peers

Countries citing papers authored by Eric W. P. Damen

Since Specialization

Citations

This map shows the geographic impact of Eric W. P. Damen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric W. P. Damen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric W. P. Damen more than expected).

Fields of papers citing papers by Eric W. P. Damen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric W. P. Damen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric W. P. Damen. The network helps show where Eric W. P. Damen may publish in the future.

Co-authorship network of co-authors of Eric W. P. Damen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric W. P. Damen. A scholar is included among the top collaborators of Eric W. P. Damen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric W. P. Damen. Eric W. P. Damen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Synthesis and Properties of 2-Oxa-6-azaspiro[3.3]heptane Sulfonate Salts 2017 ·Synthesis ·(unknown), (unknown), Jorma Hassfeld, Anastasia Hager, Peter Fey, (unknown), Eric W. P. Damen	8
2	Prediction of Maximum Yield in the Crystallization of Multicomponent Isomeric Systems 2006 ·Organic Process Research & Development ·Alan A. Smith, Ben McKay, Eric W. P. Damen, (unknown), Erik‐Jan Ras, Göran Verspui	1
3	Asymmetric Catalytic Ketone Hydrogenation: Relating Substrate Structure and Product Enantiomeric Excess Using QSPR 2005 ·QSAR & Combinatorial Science ·(unknown), Erik‐Jan Ras, (unknown), (unknown), (unknown), Paulo Dani, Göran Verspui, Alan A. Smith, Eric W. P. Damen, Ben McKay, Marcel Hoogenraad	13
4	Oxazaborolidine mediated asymmetric ketone reduction: prediction of enantiomeric excess based on catalyst structure 2004 ·Tetrahedron Asymmetry ·Marcel Hoogenraad, (unknown), Niels Elders, (unknown), Ben McKay, Alan A. Smith, Eric W. P. Damen	34
5	Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue 2002 ·Bioorganic & Medicinal Chemistry ·Eric W. P. Damen, Tapio Nevalainen, (unknown), Franciscus M. H. de Groot, Hans W. Scheeren	51
6	Novel anthracycline prodrugs 2001 ·Expert Opinion on Therapeutic Patents ·Eric W. P. Damen, (unknown), Hans W. Scheeren	14
7	Anticancer Prodrugs for Application in Monotherapy Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors 2001 ·Current Medicinal Chemistry ·Franciscus M. H. de Groot, Eric W. P. Damen, Hans W. Scheeren	101
8	Paclitaxel esters of malic acid as prodrugs with improved water solubility 2000 ·Bioorganic & Medicinal Chemistry ·Eric W. P. Damen, (unknown), (unknown), (unknown), Dick de Vos, Hans W. Scheeren	38
9	Novel anthracycline-spacer-β-glucuronide, -β-glucoside, and -β-galactoside prodrugs for application in selective chemotherapy 1999 ·Bioorganic & Medicinal Chemistry ·Ruben G.G. Leenders, Eric W. P. Damen, Edward J. A. Bijsterveld, Hans W. Scheeren, Pieter H.J. Houba, Ida H. van der Meulen‐Muileman, Epie Boven, Hidde J. Haisma	46
10	Direct conversion of 10-deacetylobaccatin III into baccatin III as a useful synthetic tool for a high yield paclitaxel semisynthesis 1998 ·Herba Polonica ·Eric W. P. Damen, (unknown), Hans W. Scheeren	1
11	Lanthanide trifluoromethanesulfonate catalysed selective acylation of 10-deacetylbaccatin III 1998 ·Tetrahedron Letters ·Eric W. P. Damen, (unknown), Hans W. Scheeren	38
12	ChemInform Abstract: Highly Diastereoselective Synthesis of Anomeric β‐O‐ Glycopyranosyl Carbamates from Isocyanates. 1997 ·ChemInform ·Ruben G.G. Leenders, (unknown), Eric W. P. Damen, Hans W. Scheeren	1
13	Highly Diastereoselective Synthesis of Anomeric β-O-Glycopyranosyl Carbamates from Isocyanates 1996 ·Synthesis ·Ruben G.G. Leenders, (unknown), Eric W. P. Damen, Hans W. Scheeren	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact